Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Lutetium (177 Lu) Chloride

Clinical utility in the molecular imaging and treatment of neuroendocrine tumours
06 May 2016
Diagnosis, Imaging and Staging;  Endocrine and neuroendocrine tumours

On 28 April 2016, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product lutetium (177 Lu) chloride (EndolucinBeta), a radiopharmaceutical precursor. EndolucinBeta is not intended for direct use in patients and must be used only for radiolabelling carrier molecules specifically developed to be used with EndolucinBeta.

The applicant for this medicinal product is ITG Isotope Technologies Garching GmbH.

EndolucinBeta will be available as a solution of 3 - 150 GBq Lutetium (177 Lu). The active substance of EndolucinBeta is lutetium (177 Lu) chloride, a radioactive isotope of lutetium that emits beta and gamma radiation.

The effect of EndolucinBeta will depend on the nature of the medicine that is radiolabelled with it. Since EndolucinBeta is only intended for administration after conjugation to carrier molecules, no clinical data with the use of EndolucinBeta alone have been submitted.

However, the clinical utility of EndolucinBeta when attached to relevant carrier molecules has been demonstrated, for example, in the molecular imaging and treatment of neuroendocrine tumours.

Unfavourable effects relating to radiation exposure of the patient and other individuals in close proximity can occur with EndolucinBeta, as is the case with all radionuclides in clinical use. These effects, which include carcinogenicity and mutagenicity, will depend on the radiation characteristics of lutetium (177 Lu) chloride in EndolucinBeta and on the carrier molecule to which EndolucinBeta is labelled. A judgement on whether the risk is acceptable in any particular case can only be made in subsequent applications for carrier molecules intending to use EndolucinBeta as a radiolabel.

The full indication is:

"EndolucinBeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabeling with Lutetium (177Lu) chloride.”

It is recommended that EndolucinBeta only be used by specialists experienced with in-vitro radiolabelling.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Last update: 06 May 2016

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.